Medicine and research reference
CagriSema (Cagrilintide + Semaglutide)
The studied cagrilintide and semaglutide combination, with trial population, outcomes and formulation limits.
Source and review status
Published sources checked
Sources checked on: 6 September 2026
Qualified clinical review: Pending. This page has not been clinically reviewed.
About this source check
AI-assisted editorial source checking covers the cited material and its stated limits. It is not a systematic review, verification of a supplied product, or clinical sign-off.
Editorial role: InfoAddict. Last material change: 6 September 2026. Next source review: 6 December 2026.
Which combination is being studied
CagriSema names the combination of cagrilintide and semaglutide. It should not be confused with cagrilintide paired with retatrutide. The REDEFINE 1 study compared the two-component treatment with each component alone and with placebo.
Sources: Garvey and colleagues, New England Journal of Medicine; indexed by Europe PMC
What REDEFINE 1 found
The 2025 report included 3,417 adults without diabetes who had obesity or overweight with a related complication. All groups received lifestyle support. At 68 weeks, the estimated average weight change was about −20.4% for the combination versus −3.0% for placebo. This was a Novo Nordisk-funded trial; an average result is not an individual forecast.
Sources: Garvey and colleagues, New England Journal of Medicine; indexed by Europe PMC
Safety and formulation limits
Gastrointestinal adverse events affected 79.6% of combination participants and 39.9% of placebo participants, usually with mild or moderate severity. The study does not validate the composition, stability or safety of a separately marketed premixed vial.
Sources: Garvey and colleagues, New England Journal of Medicine; indexed by Europe PMC
FDA’s current reference says cagrilintide is not a component of an FDA-approved drug. Trial publication and regulatory approval are separate facts.
Sources: U.S. Food and Drug Administration
Published sources
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Garvey and colleagues, New England Journal of Medicine; indexed by Europe PMC. Published 22 June 2025 online; accessed 6 September 2026.
Supports: REDEFINE 1: 3,417 participants, 68-week weight outcomes and adverse events for the studied combination.
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
U.S. Food and Drug Administration. Current FDA reference; accessed 6 September 2026.
Supports: U.S. status of retatrutide and cagrilintide and concerns about unapproved products sold for human use.
Change history
| Date | Change | Clinical-review status |
|---|---|---|
| 6 September 2026 | Source-linked reference published | Pending |
Keep a private record
UpgradeYourself lets you keep private records of routines and observations you choose to discuss with a qualified health professional. This reference does not recommend starting, stopping or changing an item.